Orchid Pharma’s ‘Exblifep’ granted European Medicines Agency
approval – A landmark achievement for India’s pharmaceuƟcal
Industry
Here is the company filing on NSE & BSE
Hope it helps.
Posts tagged Value Pickr
Orchid Pharma Ltd (30-01-2024)
Skipper Ltd., (Power and Water) a moat in making? (30-01-2024)
After paying 25% how is the remaining money called, is it generally in installments.
Suppose if I miss the due date for payment of rights or there was an error in my Asba application can I mail them and pay the remaining amount.
52 week highs and all time highs strategy (30-01-2024)
UPDATE: Powermech Projects 2900-5200 ATH,
- Base breakout seen today with volumes rising over past week.
- Weekly RSI healthly at 74.
- Trailing the stock is working. Drawdowns are a part of the journey, two 30%+ drawdowns seen in the move up.
Safe to assume bullish bias ahead.
Wockhardt – A story with twist and turn (30-01-2024)
https://www.ema.europa.eu/en/medicines/human/EPAR/exblifep
Orchid Pharma’s ‘Exblifep’ received positive recommendation from EMA.
The drug is cefepime+enmetazobactam, indicated for uses in
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
Can there be an impact on WCK 5222’s market size, given that one of the uses for this drug can be for Hospital acquired infections like VAP?
Kirloskar Electric – A Turnaround Bet? (30-01-2024)
Is there any news on this company? 20% UC today
Federal Bank – A Turnaround banking Story? (30-01-2024)
still in the previous quarter, there was a notable rise in the investment made by FII in Federal Bank. Its among top in banking sector in terms of fii investment
Orchid Pharma Ltd (30-01-2024)
Can this have any impact on the market size of WCK 5222 (cefepime+zidebactam) developed by Wockhardt, mainly targeting hospital acquired infections, ventilator associated pneumonia and other gram negative suberbugs?
Skipper Ltd., (Power and Water) a moat in making? (30-01-2024)
skipper now trades at 236 and SKIPPER-RE-BE trades at 42. The price difference between rights issue and market price is 236-194=42. so if you want to buy skipper you can directly buy from market instead of buying SKIPPER-RE-BE and later paying remaining through rights issue.
SKIPPER-RE-BE is floated mainly for people who don’t want to subscribe to rights issue and can get the small gains. Just that if they forgot to login during this week they would have missed out seeing something like this in their demat which would get extinguished after this week
Tata Investment Corporation: Unusual discount to NAV (30-01-2024)
I was holding these shares since 2011, It has never touched the number that i saw today and hence after deep thoughts i decided to part ways with the script today. I am hopeful that it will give me another opportunity to jumpin. That being said, I don’t see any reason for the stock to move up except momentum and i cant understand that, hence the decision.
Investing Basics – Feel free to ask the most basic questions (30-01-2024)
Hi. Please give more detail. Have you seen this kind of entry? Please share a screenshot